The American pharmaceutical manufacturer informed about the termination of deliveries of the drug Zepatir to the Russian Federation. This is one of the most popular drugs used in the treatment of hepatitis C.
According to Kommersant, citing a letter from the Ministry of Health and confirmation from Roszdravnadzor, the company has already informed its partners in Russia about the changes that have taken place in trade policy. At the same time, as noted, it is not a question of a literal instantaneous halt to exports. At least, this decision will not affect deliveries, which are scheduled for 2024.
It should be noted that Zepatir is among the top 3 most popular regimens for the treatment of hepatitis C genotypes 1, 3, as well as 4 in adults. In 2022, the share of this drug in government procurement amounted to 19%, in the first half of 2023 - 18%.
At the moment, there are no analogs of this drug in Russia, but a number of companies are developing generics.